The present invention generally relates to external medical apparatus. Specifically, the present invention relates to external drug pumps.
External drug pumps are typically used to deliver to patients substances which contain large molecules which cannot be digested when administered orally. They are commonly used to infuse a basal rate of insulin to subjects suffering from diabetes, as an alternative to insulin injections by an insulin syringe or an insulin pen. Typically, the pump is adhered to the abdomen of the patient and delivers the substance to the patient via a cannula that is inserted into the patient's skin.
U.S. Pat. No. 6,656,159 to Flaherty, describes a device for delivering fluid, such as insulin for example, to a patient. The device includes an exit port assembly, a syringe-like reservoir including a side wall extending towards an outlet connected to the exit port assembly. A threaded lead screw is received in the reservoir and a plunger has an outer periphery linearly slideable along the side wall of the reservoir and an inner periphery threadedly received on the lead screw. The plunger is non-rotatable with respect to the side wall such that rotating the lead screw is described as causing the plunger to advance within the reservoir and force fluid through the outlet. The device also includes a dispenser having a return element for causing rotation of the lead screw, and a shape memory element. A changeable length of the shape memory element decreasing from an uncharged length to a charged length is described as resetting the return element.
U.S. Pat. No. 6,699,218 to Flaherty, describes a device for delivering fluid to a patient, including a passageway having a proximal fluid transport tube, a distal fluid transport tube, and a tubular expansion member coupling the fluid transport tubes. A penetrating member is positioned within the expansion member for axial movement between the fluid transport tubes, and has a sharpened distal tip. The device also includes a dispenser for causing fluid from a reservoir to flow to the proximal fluid transport tube, a housing containing the dispenser and the passageway and including an exit port receiving the distal fluid transport tube, and a connecting member secured to the penetrating member. The connecting member is movable by a user from an exterior of the housing and arranged such that movement causes the penetrating member to move between an extended position for subcutaneously inserting the distal fluid transport tube into a patient, and a retracted position.
U.S. Pat. No. 6,485,461 to Mason, describes a disposable device which is described as accurately and reliably delivering an infusable liquid to a patient. The infusion device includes a housing which defines a bladder chamber. A compressible bladder is disposed in the bladder chamber and is compressed by the housing upon filling the bladder with an infusable liquid to create a pressurized bladder. The infusion devices further includes a delivery system for subcutaneously delivering the infusable liquid to a body. The delivery system includes a collapsible member that supports an injection needle and a cannula. The injection needle is used to insert the cannula into the skin of the body being treated. The cannula is in communication with the bladder during delivery of the infusable liquid. The housing includes microfluidic passageways that allow communication between fluid in the bladder and the cannula.
U.S. Pat. No. 5,851,197 to Marano, describes an injector for automatic placement of a subcutaneous infusion set or the like used for delivering a selected medication to a patient. The injector comprises a spring-loaded plunger having a head for receiving and supporting an infusion set in a position for placement of an insertion needle and related cannula through the skin of a patient at a selected insertion site. The plunger head includes a safety lock mechanism described as engaging and retaining the infusion set during spring-loaded advancement with a controlled force and speed toward the patient's skin to transcutaneously place the insertion needle and cannula. When the plunger head reaches a fully advanced position, with the infusion set placed on the patient, the infusion set is releasable from the safety lock mechanism with minimal force to permit quick and easy separation of the injector.
U.S. Pat. No. 6,960,192 to Flaherty, describes a device for delivering fluid to a person that includes a reservoir for containing a fluid to be delivered to the person; a fluid transport device for dispensing fluid from the reservoir to the person, the fluid transport device including a proximal end in fluid communication with the reservoir and a distal end having a penetrating member for piercing the skin of the person to facilitate the delivery of fluid to the person through the fluid transport device; a housing containing the reservoir and the fluid transport device, the housing including an exit port for receiving the distal end of the fluid transport device upon injection of the distal end into the person and means for securing a first wall of the housing to the skin of the person; and an injection activation device including a driving mechanism contacting the fluid transport device for driving the penetrating member from a first position within the housing, through the exit port to a second position, external to the housing and into the skin of the person.
U.S. Pat. No. 6,905,298 to Haring, describes a nut assembly that will ensure that the shank of a bolt that features a measurable grip length will pass through the contact plane of adjoining members. The nut assembly also allows the desired compressive force in the adjoining members to be attained by using a telescopic feature of the nut to allocate additional thread action for the bolt, enabling the bolt to be drawn into the nut further than what would be allowed by a standard nut. The adaptability of the nut assembly can eliminate the need for washers or shims to adjust the shank penetration of the bolt. The nut assembly is useful for applications in which the specified thread length and the grip length of the bolt is incompatible with the abutment thickness of the adjoining members.
U.S. Pat. No. 1,795,630 to Wilson, describes a screw jack that utilizes a series of telescopic screw threaded sections that may be compactly arranged in the hollow base or housing of the jack when the jack is not in use, or when only a small space is available in which the jack is to be used.
U.S. Pat. No. 5,643,218 to Lynn et al., describes a syringe for the sequential withdrawal of a first liquid and a second liquid. The syringe has a barrel, a proximal piston moveable along the barrel to define a variable volume chamber intermediate the piston and the end of the barrel, and a distal chamber divider piston for separating the variable volume chamber into primary and secondary reservoirs. A flow channel is defined along the syringe for providing flow connection between the primary and secondary reservoirs. An element links the two pistons so that as the proximal piston is moved away from the distal piston, the first liquid enters the first reservoir and thereafter the second liquid enters the secondary reservoir.
Daikyo Crystal Zenith® polymer, manufactured by Daikyo Seiko, Ltd., and used by Daikyo Seiko, Ltd. to manufacture vials, is described as being durable, non-flaking, highly transparent, very low in extractable ions, compatible with a wide pH range, and resistant to high heat.
Copaxone® (glatiramer acetate), manufactured by Teva Pharmaceutical Industries Ltd, is a drug described as helping patients who suffer from relapsing-remitting multiple sclerosis.
The following patent and patent application may be of interest:
In some embodiments of the invention, a vial is provided that contains a substance to be administered to a subject. The vial is sealed by a stopper, and has therein first and second threaded elements (e.g., a screw and a nut) that are threadedly coupled to each other. The first threaded element is rotatable with respect to the vial, and is linearly immobile with respect to the vial during rotation of the first threaded element. The first threaded element, by rotating, is configured to linearly advance the stopper and at least the distal end of the second threaded element toward the distal end of the vial, without substantially rotating the second threaded element and the stopper. The distal end of the second threaded element defines a coupling portion that couples the second threaded element to the stopper.
In some embodiments, the stopper impedes rotation of the second threaded element, for example, friction between the stopper and the inside of the vial impedes rotation of the second threaded element. Alternatively or additionally, the vial is shaped such that the vial impedes rotation of the second threaded element.
For some applications, the threaded elements are used in conjunction with a standard, commercially-available vial and/or stopper.
Typically, the distal end of the first threaded element is configured to remain proximal to the stopper, or proximal to a distal end of the stopper, and the proximal end of the second threaded element is configured to remain proximal to the distal end of the stopper at all times during the rotating of the first threaded element.
Typically, the apparatus comprises a housing base, the vial and the threaded elements being configured to be inserted into or otherwise coupled to the housing base. For some applications, a portion of the housing base is configured to automatically displace the threaded elements and the stopper toward a distal end of the vial during the insertion into the housing base.
In some embodiments, the subject couples a housing top to the housing base after the vial is inserted into the housing base. The housing top typically contains a motor and a cog, the motor configured to rotate the cog and the cog configured to rotate the first threaded element. For some applications, a control unit administers a basal rate of the substance to the subject by controlling the motor. Alternatively or additionally, the control unit is configured to receive an input and to administer a bolus of the substance to the subject responsively to the input. Further alternatively or additionally, the control unit controls the administering of the substance to the subject in response to the detection by a sensor of one or more physiological parameters of the subject.
For some applications, the substance is administered to the subject via a cannula. Typically, the cannula surrounds a needle. The cannula is inserted into the subjects skin by piercing the subject's skin with the needle and inserting the needle. The needle is typically retracted from the subject's skin following the piercing and the cannula remains inserted in the subject's skin for the duration of the time that the substance is administered to the subject.
In some applications, the apparatus comprises a skin-piercing activation mechanism. Piercing the subject's skin comprises rapidly piercing the subject's skin by displacing a force-receiving element of an activation mechanism. The application of a force to the activation mechanism that exceeds a threshold force displaces the force-receiving element. For example, the subject may press a button coupled to the housing base or top, and, upon application of force that exceeds the threshold force, the needle is suddenly released, and rapidly pierces the skin.
It is noted that the use of two separate portions, the housing top and the housing base, facilitates easier sterilization of components that should be sterilized—particularly the tissue-contacting components of the housing base. The housing top, which typically comprises the battery, motor, and associated electronics, is not typically sterilized.
Additionally, for added convenience of use by the subject, the housing top may be easily removed prior to showering. Alternatively or additionally, all of the components in the housing top are waterproof, such that the housing top may remain coupled to the housing bottom while the subject showers.
In some embodiments, the vial comprises (for example, the vial may be composed of) a cyclic olefin polymer, such as Crystal Zenith®.
There is therefore provided, in accordance with an embodiment of the present invention, apparatus for administering a substance to a subject, including: a vial that contains the substance; a stopper within the vial, slidably coupled to the vial; a first threaded element (a) rotatable with respect to the vial and (b) substantially immobile proximally with respect to the vial during rotation of the first threaded element; and a second threaded element that is threadedly coupled to the first threaded element, at least a distal end of the second threaded element substantially non-rotatable with respect to the vial, the distal end of the second threaded element defining a coupling portion that couples the second threaded element to the stopper, and the first threaded element, by rotating, linearly advancing the stopper and at least the distal end of the second threaded element toward a distal end of the vial.
In an embodiment, the apparatus further includes: a vial housing unit that houses the vial and the threaded elements; a needle housing unit coupled to the vial housing unit and not rigidly connected to the housing unit; a needle housed within the needle housing unit; and a cannula at least partially disposed around the needle, and the apparatus is configured to administer the substance to the subject via the cannula.
In an embodiment, the distal end of the second threaded element is disposed at least partially within the stopper.
In an embodiment, the second threaded element is configured to be coupled to the stopper by a user.
In an embodiment, the second threaded element is provided to a user, the second threaded element already coupled to the stopper.
In an embodiment, the vial includes a circular barrel having an inner surface that is smooth.
In an embodiment, the substance includes insulin and the insulin is disposed within the vial.
In an embodiment, a distal end of the first threaded element remains proximal to a proximal end of the stopper at all times during the rotating of the first threaded element.
In an embodiment, the apparatus further includes a dividing stopper within the vial, slidably coupled to the vial; the vial includes a distal compartment and a proximal compartment, the distal compartment containing a powder and the proximal compartment containing a liquid, the dividing stopper reversibly inhibiting fluid communication between the distal compartment and the proximal compartment, and the first threaded element, by rotating, mixes the powder and the liquid by advancing the dividing stopper toward the distal end of the vial.
In an embodiment, a distal end of the second threaded element is configured to remain proximal to a distal end of the stopper at all times during the rotating of the first threaded element.
In an embodiment, the apparatus further includes a housing base, the vial and the first and second threaded elements are configured to be inserted into the housing base, and a portion of the housing base is configured to impede proximal linear motion of the first threaded element during rotation of the first threaded element.
In an embodiment, the first threaded element includes thread that defines a maximal diameter and a pitch, and a ratio between the maximal diameter and the pitch is 6:1 to 15:1.
In an embodiment, friction between the stopper and an inner surface of the vial impedes rotation of the second threaded element.
In an embodiment, friction between the stopper and an inner surface of the vial impedes rotation of the second threaded element while allowing distal motion of the second threaded element.
In an embodiment, the apparatus further includes a housing base, the vial and the first and second threaded elements are configured to be inserted into the housing base, and a portion of the housing base is configured to displace the threaded elements and the stopper toward the distal end of the vial during the insertion into the housing base.
In an embodiment, the portion of the housing base is configured to apply a sufficient force, in displacing the threaded elements and the stopper, to overcome friction between the stopper and the vial that is due to prolonged storage of the stopper in contact with the vial.
In an embodiment, the apparatus further includes a cannula coupled to the housing base and configured to be inserted into skin of the subject, and the housing base, by displacing the threaded elements and the stopper, is configured to expel gas through a distal end of the cannula.
In an embodiment, the portion of the housing base, by displacing the threaded elements and the stopper, is configured to expel at least some of the substance through the distal end of the cannula.
In an embodiment, the portion of the housing base is disposed with respect to a portion at a proximal end of the vial such that, during the insertion of the vial and the threaded elements into the housing base, relative motion between the portion of the housing base and the portion at the proximal end of the vial displaces the threaded elements and the stopper toward the distal end of the vial.
In an embodiment, the portion of the housing base is disposed such that sliding motion between the portion of the housing base and the portion at the proximal end of the vial advances the threaded elements and the stopper toward the distal end of the vial.
In an embodiment, the apparatus further includes: at least one cog that is couplable to a proximal end of the first threaded element and configured to rotate the first threaded element by rotating; a motor configured to rotate the cog; and a housing top, to which the cog and the motor are coupled.
In an embodiment, the apparatus further includes a control unit coupled to the motor, and the control unit is configured to receive a coded indication of a characteristic of the substance, and to control the motor in response to the indication of the characteristic of the sub stance.
In an embodiment, the apparatus further includes a control unit coupled to the motor, and the control unit is programmable and is configured to be programmed to administer a basal rate of the substance to the subject by controlling the motor.
In an embodiment, the apparatus further includes a control unit coupled to the motor, and the control unit is configured to receive an input and to administer a bolus of the substance to the subject responsively to the input.
In an embodiment, the apparatus further includes: a control unit coupled to the motor; and a sensor configured to detect a physiological parameter of the subject and to transmit a signal to the control unit responsively to the parameter, and the control unit is configured to control the motor responsively to the signal.
In an embodiment, the sensor is configured to be implanted in the subject's body.
In an embodiment, the sensor is configured to transmit the signal wirelessly.
In an embodiment, the apparatus further includes a housing base configured to hold the vial, and the housing base and the housing top are configured to be coupled together by the subject prior to the administering of the substance, and decoupled from each other by the subject following the administering of the substance.
In an embodiment, the housing top is configured to be reused subsequent to the administering of the substance from the vial, and the housing base and the threaded elements are configured to be discarded subsequent to the administering of the substance from the vial.
In an embodiment, the apparatus further includes: one or more magnetic elements coupled to the housing base; and one or more magnetic elements coupled to the housing top, and the magnetic elements are configured to reversibly magnetically couple the housing base to the housing top when the housing base and housing top are aligned.
In an embodiment, the apparatus further includes: a housing base, and the vial and the threaded elements are configured to be inserted into the housing base; a needle coupled to the housing base; and a cannula at least partially disposed around the needle, the needle is configured to pierce skin of the subject and insert the cannula into the subject's skin, the needle is configured to retract subsequent to piercing, and the apparatus is configured to administer the substance to the subject via the cannula.
In an embodiment, the apparatus further includes a needle activation mechanism coupled to the needle, the needle activation mechanism including: a subject-contact surface for application thereto of a force by the subject; and a force-receiving element which is configured to be displaced when the force applied by the subject to the subject-contact surface exceeds a threshold force, and the needle is configured to rapidly pierce the skin in response to displacement of the force-receiving element due to the force exceeding the threshold force.
In an embodiment, the apparatus further includes a spring, and the spring is configured to retract the needle subsequent to the piercing.
In an embodiment, the apparatus further includes: a housing base, the vial and the threaded elements being configured to be inserted into the housing base; and a needle coupled to the housing base and configured to pierce skin of the subject, and the apparatus is configured to administer the substance to the subject via the needle.
In an embodiment, the apparatus is configured to administer substantially all of the substance in less than one hour.
In an embodiment, the substance includes glatiramer acetate and the apparatus is configured to deliver the glatiramer acetate to the subject via the needle.
In an embodiment, the apparatus further includes: a housing base, the vial and the threaded elements being configured to be inserted into the housing base; and a plurality of microneedles coupled to the housing base and configured to pierce skin of the subject, and the apparatus is configured to administer the substance to the subject via the plurality of microneedles.
In an embodiment, a diameter of each of the microneedles is less than 150 microns.
In an embodiment, the first threaded element includes a screw, and the second threaded element includes a nut disposed at least partially around the screw.
In an embodiment, the screw includes a telescopic screw, and the screw is configured to advance a distal end of the nut toward the distal end of the vial by extending the telescopic screw toward the distal end of the vial.
In an embodiment, the telescopic screw includes two at least partially overlapping portions.
In an embodiment, the telescopic screw includes three or more at least partially overlapping portions.
In an embodiment, the nut includes a telescopic nut, and the screw is configured to advance a distal end of the nut toward the distal end of the vial by extending the telescopic nut toward the distal end of the vial.
In an embodiment, the telescopic nut includes two at least partially overlapping portions.
In an embodiment, the telescopic nut includes three or more at least partially overlapping portions.
In an embodiment, the first threaded element includes a nut, and the second threaded element includes a screw disposed at least partially inside the nut.
In an embodiment, the screw includes a telescopic screw, and the nut is configured to advance a distal end of the screw toward the distal end of the vial by extending the telescopic screw toward the distal end of the vial.
In an embodiment, the telescopic screw includes two at least partially overlapping portions.
In an embodiment, the telescopic screw includes three or more at least partially overlapping portions.
In an embodiment, the nut includes a telescopic nut, and the nut is configured to advance a distal end of the screw toward the distal end of the vial by extending the telescopic nut toward the distal end of the vial.
In an embodiment, the telescopic nut includes two at least partially overlapping portions.
In an embodiment, the telescopic nut includes three or more at least partially overlapping portions.
There is additionally provided, in accordance with an embodiment of the present invention, a method, including: providing: a vial that contains a substance, and is sealed by a stopper, and first and second threaded elements for placement within the vial, the first and second threaded elements being threadedly coupled to each other, a distal end of the second threaded element being for coupling to the stopper; inserting the vial into a housing base, the threaded elements having been inserted into the vial, and the distal end of the second threaded element having been coupled to the stopper; and pushing the substance out of the vial by advancing the stopper and at least the distal end of the second threaded element toward a distal end of the vial, the advancing being performed by: rotating the first threaded element with respect to the vial, impeding proximal linear motion of the first threaded element with respect to the vial during rotation of the first threaded element, and impeding rotational motion of at least the distal end of the second threaded element with respect to the vial.
There is further provided, in accordance with an embodiment of the present invention, apparatus for administering a substance to a subject, including: a vial that contains the substance; a stopper within the vial, slidably coupled to the vial; a shaft within the vial, a distal portion of the shaft being coupled to the stopper; and a rotation mechanism disposed proximally to the vial, coupled to the shaft and configured to linearly advance the stopper toward a distal end of the vial by rotating the shaft, and at all times during the rotating of the shaft, (a) a distal end of the shaft is configured to remain proximal to a distal end of the stopper, and (b) a proximal end of the shaft is configured to remain distal to a proximal end of the rotation mechanism.
There is additionally provided, in accordance with an embodiment of the present invention, a method, including: providing a vial that contains a substance, is sealed by a stopper, and has therein a shaft that is coupled to the stopper; inserting the vial into a housing base, a rotation mechanism being coupled to the housing base proximally to the vial; pushing the substance out of the vial by advancing the stopper by rotating the shaft; maintaining a distal end of the shaft proximal to a distal end of the stopper at all times during the rotating of the shaft; and maintaining a proximal end of the shaft distal to a proximal end of the rotation mechanism at all times during the rotating of the shaft.
There is further provided, in accordance with an embodiment of the present invention, apparatus for administering a substance to a subject, including: a vial that contains the substance; a stopper within the vial, slidably coupled to the vial; a first threaded element (a) rotatable with respect to the vial and (b) substantially immobile proximally with respect to the vial during rotation of the first threaded element; and a second threaded element that is threadedly coupled to the first threaded element, at least a distal end of the second threaded element substantially non-rotatable with respect to the vial, the distal end of the second threaded element remaining proximal to a distal end of the stopper at all times during rotation of the first threaded element, and the first threaded element, by rotating, linearly advancing the stopper and at least the distal end of the second threaded element toward a distal end of the vial.
There is additionally provided, in accordance with an embodiment of the present invention, a method, including: providing: a vial that contains a substance, and is sealed by a stopper, and [0158] first and second threaded elements for placement within the vial, the first and second threaded elements being threadedly coupled to each other, a distal end of the second threaded element being for coupling to the stopper; inserting the vial into a housing base, the threaded elements having been inserted into the vial, and the distal end of the second threaded element having been coupled to the stopper; pushing the substance out of the vial by advancing the stopper and at least the distal end of the second threaded element toward a distal end of the vial, the advancing being performed by: rotating the first threaded element with respect to the vial, impeding proximal linear motion of the first threaded element with respect to the vial during rotation of the first threaded element, and impeding rotational motion of at least the distal end of the second threaded element with respect to the vial; and maintaining the distal end of the second threaded element proximal to a distal end of the stopper at all times during the rotating of the first threaded element.
The foregoing summary, as well as the following detailed description of a preferred embodiment of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings an embodiment which is presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown.
In the drawings:
Certain terminology is used in the following description for convenience only and is not limiting. The words “right,” “left,” “lower” and “upper” designate directions in the drawings to which reference is made. The words “inwardly” and “outwardly” refer to directions toward and away from, respectively, the geometric center of the device and designated parts thereof. Unless specifically set forth herein, the terms “a”, “an” and “the” are not limited to one element but instead should be read as meaning “at least one”. The terminology includes the words noted above, derivatives thereof and words of similar import.
Reference is now made to
In some embodiments, first threaded element 26 is a nut and second threaded element 28 is a screw disposed at least in part inside the nut. The nut is configured to rotate and to cause the screw and the stopper to advance toward a distal end of the vial due to the rotation of the nut. Alternatively, the first threaded element is a first screw and the second threaded element is a second screw. The first screw is configured, by rotating, to advance the second screw and the stopper toward the distal end of the vial. In general, apparatus 20 comprises a first threaded element that rotates, but is substantially immobile linearly during rotation of the first threaded element, and a second threaded element that (a) is substantially non-rotatable, (b) moves linearly toward the distal end of the vial in response to the rotation of the first threaded element, and (c) is coupled to the stopper. The first threaded element is rotated, causing the second threaded element and the stopper to advance distally.
Typically, vial 22 is inserted into a housing base 32. In some embodiments, portion 34 of the housing base is configured to impede proximal linear motion of first threaded element 26. (In the context of the present patent application and in the claims, the term “proximal” denotes a position toward an end 38 of the vial. The term “distal” denotes a position toward an end 36 of the vial, out of which the substance is administered to the subject.) In some embodiments, during rotation of first threaded element 26, stopper 24 is configured to impede rotation of second threaded element 28. Typically, friction of the stopper against the inside of the vial impedes rotational motion of the stopper, and element 28 being coupled to the stopper is similarly impeded. Thus, as first threaded element 26 is rotated, second threaded element 28 and the stopper advance linearly toward distal end 36 of the vial. In some embodiments, a standard, commercially-available vial and stopper are used as vial 22 and stopper 24. For some applications, the first and second threaded elements are standard, commercially-available threaded elements, e.g., a standard commercially-available screw and nut. Friction between the stopper and the vial impedes rotation of the stopper, while allowing distal movement of the stopper within the vial, as described in further detail herein below, with reference to
For some applications, rotation of the second threaded element is impeded by other means, for example, as described herein below.
For some applications, the initial position of stopper 24 in vial 22 is in accordance with the amount of the substance that is contained within the vial and that is to be administered to the subject. The lengths of first and second threaded elements 26 and 28 are typically such that when the threaded portions of the elements are maximally overlapping (i.e., fully screwed together), and the elements are disposed within the vial, coupling portion 30 couples the second threaded element to the stopper. For example, the lengths of the screw and the nut, shown in
In an alternative embodiment, first and second threaded elements 26 and 28 are placed in the vial, without being selected based on the initial volume of substance, and the elements are unscrewed from each other a suitable amount in order to facilitate the coupling of coupling portion 30 to the stopper.
Typically, a distal end 40 of the first threaded element 26 is configured to remain proximal to the stopper, or proximal to distal end 43 of the stopper, at all times during the rotating of the first threaded element. Further typically, the distal end of the second threaded element remains proximal to the distal end of the stopper at all times during the rotation of the first threaded element. The stopper typically provides a seal between a first portion of the vial, which is distal to the stopper, and a second portion of the vial, which is proximal to the stopper. In some embodiments, the sterility of the substance disposed in the first portion is maintained by the stopper providing a seal between the first portion and the second portion, threaded elements being disposed in the second portion. The first and second threaded elements assembly may be viewed as a shaft that converts the rotational motion of motor 50 to distal advancement of stopper 24. Typically, at all times during the rotating of the shaft, (a) the distal end of the shaft (i.e., the distal end of the second threaded element) is configured to remain proximal to a distal end of the stopper, and (b) the proximal end of the shaft (i.e., the proximal end of the first threaded element) is configured to remain distal to a proximal end of the rotation mechanism.
For some applications, a vial piercing mechanism 44 is movably (e.g., rotatably) coupled to housing base 32. As part of the insertion of vial 22 into the housing base, a seal 46 at distal end 36 of the vial is pierced by pressing the seal against the piercing mechanism. The substance is configured to subsequently flow through a tube 53 toward an activation mechanism 56, which is typically coupled to the housing base, and is configured to insert a cannula and/or a needle through the subject's skin and to deliver the substance via the cannula and/or the needle.
Although first and second threaded elements 26 and 28 have been described as being within vial 22 (e.g., the apparatus may be bought by the subject with the threaded elements already within the vial), in some embodiments, the threaded elements are inserted into the vial and are coupled to stopper 24 by the subject and/or by a healthcare provider. In some embodiments, vial 22 and stopper 24 are a standard, commercially-available vial and stopper, for example, the vial may be a circular barrel with a smooth inner wall. The first and second threaded elements are inserted into the vial and coupled to the stopper, and the apparatus dispenses the substance, in accordance with the techniques described hereinabove. The friction between the standard stopper and the standard vial prevent the second threaded element from rotating due to the coupling of the second threaded element to the stopper, as described hereinabove. For some applications, providing the apparatus described herein for use with standard, commercially-available vials and stoppers provides a commercial advantage.
For some applications, the threaded elements are coupled to housing base 32, and the subject and/or a healthcare provider moves the vial with respect to the housing base in order to couple the stopper to the second threaded element. For example, a standard, commercially-available vial and stopper may be moved with respect to the housing base, in order to couple the stopper to the second threaded element, the threaded elements being coupled to the housing base.
In some embodiments, a housing top 48 is coupled by the subject to housing base 32. The housing top typically comprises a motor 50 and a battery 58. (In an embodiment, the battery is coupled to housing base 32.) For some applications, a first cog 52 (i.e., a motor cog) is coupled to housing base 32. The motor is configured to rotate the first cog 52, and the first cog 52 is configured to rotate first threaded element 26. Typically, first cog 52 engages a second cog 54, the second cog 54 being coupled to the proximal end of threaded element 26, and/or comprising the proximal portion of threaded element 26. In some embodiments, only a single cog is used, the single cog being coupled to and/or comprising a proximal portion of threaded element 26, and the single cog being rotated directly by the motor. Alternatively or additionally, other techniques known in the art are used for converting motion from a motor to rotational or linear motion.
For some applications, the subject reversibly couples the housing top to housing base 32. Following the termination of the delivery of the substance to the subject from vial 22, the subject and/or a healthcare provider decouples the housing top from the housing base. In some embodiments, the housing top is configured to be re-used with another housing base, and the housing base is configured to be discarded after a single use. For some applications, the housing top and the housing base comprise magnetic materials 59 that are configured to releasably couple the housing top to the housing base when the top and the base are aligned.
For some applications, a control unit 51 is coupled to motor 50. In some embodiments, the control unit administers a basal rate of the substance to the subject by controlling the motor. Alternatively or additionally, the control unit is configured to receive an input and to administer a bolus of the substance to the subject responsively to the input. For example, housing top 48 may comprise two buttons. When both buttons are pressed at the same time, the control unit is configured to administer a bolus of the drug. Alternatively, a button 80 associated with activation mechanism 56 may be configured to cause the control unit to administer a bolus of the drug, when pushed subsequent to the insertion mechanism having been activated. Further alternatively or additionally, a sensor 57 (shown in
In some embodiments, vial 22 has a distal compartment which contains a powder, and a proximal compartment which contains a liquid. The distal compartment and the proximal compartment are reversibly separated by a dividing stopper 134 (shown in
Reference is now made to
In some embodiments, as vial 22 is lowered into housing base 32, first cog 52 engages second cog 54. For some applications, as the vial is lowered, portion 34 of the housing base automatically displaces first and second threaded elements 26 and 28 (and therefore stopper 24) toward distal end 36 of the vial. In some embodiments, the stopper is disposed within the vial such that before the insertion of the vial into the housing, first threaded element 26 protrudes a distance h from the proximal end of the vial. The proximal end of the first threaded element (or of second cog 54) comprises a rounded portion 74. Portion 34 of the housing base comprises an angled face 76. As rounded portion 74 slides past the angled face, the first threaded element is pushed the distance h inside the vial. As a result, the threaded elements and the stopper are displaced toward the distal end of the vial.
In some embodiments, apparatus 20 comprises alternative means of pushing threaded elements 26 and 28 inside vial 22 during the insertion of the vial into housing base 32. For example, the proximal end of first threaded element 26 may comprise an angled face and portion 34 of the housing base may comprise a rounded portion. Alternatively, both the proximal end of the first threaded element and portion 34 of the housing may comprise an angled face and/or a rounded portion.
For some applications, portion 34 of housing base 32 is configured to apply a sufficient force, in displacing threaded elements 26 and 28 and stopper 24, to overcome friction between stopper 24 and vial 22 that is due to prolonged storage of the stopper in contact with the vial. For example, the stopper may have been stored in contact with the inner surface of the vial for a period of at least one week or longer, as a result of which the stopper may have a higher effective static friction than would have existed if the stopper had been recently moved with respect to the vial. Alternatively or additionally, apparatus 20 comprises a cannula 100 and/or a needle 102 (as shown in
Reference is now made to
Reference is now made to
During insertion of the vial into the housing base, the first and second threaded elements and the stopper are displaced toward distal end 36 of the vial, as shown in
First threaded element 26 rotates during administration of the substance to the subject. Rotational motion of second threaded element 28 is impeded (even if not necessarily eliminated) by stopper 24 to which the second threaded element is coupled, and/or rotational motion of the second threaded element is impeded by alternative means, for example, as described with reference to
Typically, due to the rotation of the first threaded element, a linear force FL and a rotational force FR act on stopper 24, as shown in
In a more detailed analysis of this effect, it is noted that, in some embodiments, friction between the stopper and the vial has the aforementioned effect due to selection of a suitable ratio of (a) the maximal diameter D of the first threaded element (shown in
By way of example, the first threaded element may have a maximal diameter of 8 mm and a pitch of 1 mm (i.e., a ratio of maximal diameter to pitch of 8:1). Accordingly, the outer perimeter of the first threaded element is greater than 25 mm (pi multiplied by the maximal diameter). As the first threaded element rotates through 360 degrees, if the second threaded element were to unscrew from the first threaded element by rotating, the second threaded element would rotate through a distance of more than 25 mm, around the perimeter of the first threaded element. Accordingly, the outer surface of the stopper would rotate in contact with the inner surface of the vial through an even greater distance, such as 40 mm (since the outer diameter of the stopper is greater than that of the first threaded element, as seen, for example, in any of
It is noted that in some embodiments, friction between the stopper and the vial acts to impede rotation of the stopper, while allowing distal movement of the stopper within the vial, generally irrespective of the ratio of the maximal diameter D to the pitch P of the first threaded element.
As disclosed hereinabove, in some embodiments, friction acts to impede rotation of the stopper, while allowing distal movement of the stopper within the vial, even when the apparatus disclosed herein is used in conjunction with standard, commercially-available vials, stoppers, and threaded elements.
Reference is now made to
The pushing of button 80 with sufficient force causes structural element 103 to advance toward the subject's skin. When the structural element arrives at the end of its travel, it is held in place by holding portion 108. For example, a proximal portion of protrusion 104 may be secured by a distally-directed force applied thereto by a distal portion of force receiving element 106, constituting holding portion 108, as shown in
In an alternative embodiment, the substance is administered to the subject via needle 102, the needle remaining inserted in the subject's skin for the duration of the administration. In such an embodiment, apparatus 20 is typically configured to administer substantially all of the substance to the subject in less than one hour. For example, Copaxone® (or another drug) may be administered to the subject in this manner over the course of approximately one half hour.
In some embodiments, needle 102 comprises a plurality of microneedles, which are inserted into the subject's skin, and the substance is administered to the subject via the microneedles. Typically, the diameter of each of the microneedles is about 50-150 microns, e.g., about 100 microns, and the length of each of the microneedles is about 200-1000 microns.
In an embodiment, control unit 51 is configured to receive an indication, on vial 22, first threaded element 26, second threaded element 28, or another element, that indicates a characteristic of the contents of vial 22. For example, a barcode, RFID, mechanical code, or other code may indicate to the control unit the type of pharmaceutical product in the vial, the quantity of the substance, or a dosage schedule for administration of the substance. Typically, when the subject first receives the vial, stopper 24 is already in place within the vial at the correct position for initiating delivery of the substance.
Reference is now made to
In some embodiments, vial 22 contains (for example, the vial may be composed of) a cyclic olefin polymer, such as Crystal Zenith®. In some embodiments, manufacturing the vial using a cyclic olefin polymer facilitates the molding of protrusion 120. For some applications, stopper 24 is coated with a fluoropolymer. Typically, using a vial that contains a cyclic olefin polymer, and/or a stopper that is coated with a fluoropolymer maintains the stability of a substance that is disposed within the vial. For example, the vial may be used to administer a monoclonal antibody to the subject, and the composition of the vial, the stopper, and/or the second threaded element may maintain the stability of the monoclonal antibody.
In some embodiments, the proximal end of vial 22 is shaped to define two or more flanges 123. Typically, the flanges facilitate the filling of the vial. For example, during the filling of the vial, the vial may be placed inside a hole of a tray, and the flanges may support the vial inside the hole. In some embodiments, the flanges are configured to hold the vial in a fixed position inside housing base 32.
Reference is now made to
Reference is now made to
It is noted that the term “providing” as used herein in the specification and in the claims, in the context of providing apparatus (for example, providing a vial), includes within its scope the apparatus being provided by the user of the apparatus, and is not limited to the sale of the apparatus.
Reference is now made to
In some embodiments (as shown in
Reference is now made to
In some embodiments, the second threaded element is a telescopic screw. First threaded element, by rotating, extends the telescopic screw and advances stopper 24 and distal end 152 of the telescopic screw toward distal end 36 of vial 22, in accordance with the techniques described hereinabove. In some embodiments, using a telescopic screw as the second threaded element facilitates the use of a smaller length vial to administer a given amount of the substance than would be necessary if a non-telescopic screw, or a nut were used as the second threaded element. In some embodiments, a telescopic screw is used as the first threaded element, and a nut is used as the second threaded element.
Although a telescopic screw having two overlapping portions 154 and 156 is shown, the scope of the present invention includes using a screw having more three or more overlapping portions as the second threaded element of vial 22. Typically, the ratio of the length of the telescopic screw when fully extended to the length of the telescopic screw when fully contracted (as shown in
In some embodiments, as shown in
Reference is now made to
Vial 22 of
Reference is now made to
In some embodiments, activation mechanism 56 is housed in needle housing unit 172. The activation mechanism, as described hereinabove, inserts cannula 100 and/or needle 102 through the subject's skin and delivers the substance via the cannula and/or the needle. Vial 22 and control components, such as motor 50 and battery 58, are housed separately in vial housing unit 170. In some embodiments, needle housing unit 172 is adhered to the subjects skin, and vial housing unit 170 is not adhered to the subject's skin. Typically, the needle housing unit and the vial housing unit are not rigidly connected to each other. For example, vial housing unit 170 may be worn on the subject's belt, or elsewhere on the subject's clothing. Typically, vial housing unit 170 is coupled to needle housing unit 172 via tube 53, via which the substance flows from the vial toward activation mechanism 56.
It is noted that, although a specific configuration of activation mechanism 56 is shown, in some embodiments, needle housing unit 172 houses an activation mechanism having a different configuration. For example, needle housing unit 172 may house only cannula 100 and/or needle 102. The subject inserts the needle into the subject's skin by adhering the needle housing unit to the skin.
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
This application is a divisional of U.S. patent application Ser. No. 14/593,051, filed on Jan. 9, 2015, entitled “External Drug Pump,” which is a continuation of similarly-titled U.S. patent application Ser. No. 12/244,666, filed on Oct. 2, 2008 and issued on Nov. 3, 2015 as U.S. Pat. No. 9,173,997, which claims the benefit of similarly-titled U.S. Provisional Patent Application No. 60/997,459, filed on Oct. 2, 2007, the contents of each of which are incorporated by reference herein in their entirety. The present application is related to U.S. patent application Ser. No. 12/244,688, filed on Oct. 2, 2008, entitled “External Drug Pump,” the contents of which are incorporated by reference herein. The application is also related to International Patent Application No. PCT/IL2008/001312, filed on Oct. 2, 2008, entitled “External Drug Pump,” the contents of which are incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
232432 | Allison | Sep 1880 | A |
1795630 | Wilson | Mar 1931 | A |
2677373 | Barradas | May 1954 | A |
2702547 | Glass | Feb 1955 | A |
2860635 | Wilburn | Nov 1958 | A |
3203269 | Perrine | Aug 1965 | A |
3212685 | Swan et al. | Oct 1965 | A |
3623474 | Heilman et al. | Nov 1971 | A |
4195636 | Behnke | Apr 1980 | A |
4254768 | Ty | Mar 1981 | A |
4273122 | Whitney et al. | Jun 1981 | A |
4300554 | Hessberg et al. | Nov 1981 | A |
4403987 | Gottinger | Sep 1983 | A |
4435173 | Siposs et al. | Mar 1984 | A |
4465478 | Sabelman et al. | Aug 1984 | A |
4502488 | Degironimo et al. | Mar 1985 | A |
4504263 | Steuer et al. | Mar 1985 | A |
4564054 | Gustavsson | Jan 1986 | A |
4585439 | Michel | Apr 1986 | A |
4599082 | Grimard | Jul 1986 | A |
4664654 | Strauss | May 1987 | A |
4685903 | Cable et al. | Aug 1987 | A |
4698055 | Sealfon | Oct 1987 | A |
4735311 | Lowe et al. | Apr 1988 | A |
4810215 | Kaneko | Mar 1989 | A |
4867743 | Vaillancourt | Sep 1989 | A |
4882575 | Kawahara | Nov 1989 | A |
4892521 | Laico et al. | Jan 1990 | A |
4919596 | Slate et al. | Apr 1990 | A |
4964866 | Szwarc | Oct 1990 | A |
5051109 | Simon | Sep 1991 | A |
5112317 | Michel | May 1992 | A |
5190521 | Hubbard et al. | Mar 1993 | A |
5300045 | Plassche, Jr. | Apr 1994 | A |
5318522 | D'Antonio | Jun 1994 | A |
5478315 | Brothers et al. | Dec 1995 | A |
5501665 | Jhuboo et al. | Mar 1996 | A |
5562624 | Righi et al. | Oct 1996 | A |
5624400 | Firth et al. | Apr 1997 | A |
5637095 | Nason et al. | Jun 1997 | A |
5643218 | Lynn et al. | Jul 1997 | A |
5645530 | Boukhny et al. | Jul 1997 | A |
5647853 | Feldmann et al. | Jul 1997 | A |
5658256 | Shields | Aug 1997 | A |
5662678 | Macklin | Sep 1997 | A |
5728075 | Levander | Mar 1998 | A |
5766186 | Faraz et al. | Jun 1998 | A |
5810784 | Tamaro | Sep 1998 | A |
5830187 | Kriesel et al. | Nov 1998 | A |
5851197 | Marano et al. | Dec 1998 | A |
5858001 | Tsals et al. | Jan 1999 | A |
5893842 | Imbert | Apr 1999 | A |
5894015 | Rechtin | Apr 1999 | A |
5919167 | Mulhauser et al. | Jul 1999 | A |
5926596 | Edwards et al. | Jul 1999 | A |
5944699 | Barrelle et al. | Aug 1999 | A |
5968011 | Larsen et al. | Oct 1999 | A |
5989221 | Hjertman | Nov 1999 | A |
5993423 | Choi | Nov 1999 | A |
6033245 | Yamkovoy | Mar 2000 | A |
6045533 | Kriesel et al. | Apr 2000 | A |
6186982 | Gross et al. | Feb 2001 | B1 |
6200296 | Dibiasi et al. | Mar 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6270481 | Mason et al. | Aug 2001 | B1 |
6287283 | Ljunggreen et al. | Sep 2001 | B1 |
6302633 | Poe | Oct 2001 | B1 |
6485461 | Mason et al. | Nov 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6511336 | Turek et al. | Jan 2003 | B1 |
6554800 | Nezhadian et al. | Apr 2003 | B1 |
6565541 | Sharp | May 2003 | B2 |
6595956 | Gross et al. | Jul 2003 | B1 |
6656159 | Flaherty | Dec 2003 | B2 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6722916 | Buccinna et al. | Apr 2004 | B2 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6749587 | Flaherty | Jun 2004 | B2 |
6800071 | McConnell et al. | Oct 2004 | B1 |
6905298 | Haring | Jun 2005 | B1 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6997727 | Legrady et al. | Feb 2006 | B1 |
7033338 | Vilks et al. | Apr 2006 | B2 |
7034223 | Fan et al. | Apr 2006 | B2 |
7060054 | Nissels | Jun 2006 | B2 |
7225694 | Said | Jun 2007 | B2 |
7250037 | Shermer et al. | Jul 2007 | B2 |
7291132 | DeRuntz et al. | Nov 2007 | B2 |
7291159 | Schmelzeisen-Redeker et al. | Nov 2007 | B2 |
7407493 | Cane′ | Aug 2008 | B2 |
7442186 | Blomquist | Oct 2008 | B2 |
7488181 | van Haaster | Feb 2009 | B2 |
7501587 | English | Mar 2009 | B2 |
7503786 | Kato et al. | Mar 2009 | B2 |
7540858 | DiBiasi | Jun 2009 | B2 |
7704088 | Sakamoto | Apr 2010 | B2 |
7717903 | Estes et al. | May 2010 | B2 |
7736344 | Moberg et al. | Jun 2010 | B2 |
7766867 | Lynch et al. | Aug 2010 | B2 |
7794426 | Briones et al. | Sep 2010 | B2 |
7938803 | Mernoe et al. | May 2011 | B2 |
7967795 | Cabiri | Jun 2011 | B1 |
8057436 | Causey et al. | Nov 2011 | B2 |
8062253 | Nielsen et al. | Nov 2011 | B2 |
8105293 | Pickhard | Jan 2012 | B2 |
8152779 | Cabiri | Apr 2012 | B2 |
8157769 | Cabiri | Apr 2012 | B2 |
8172591 | Wertz | May 2012 | B2 |
8177749 | Slate et al. | May 2012 | B2 |
8221356 | Enggaard et al. | Jul 2012 | B2 |
8348898 | Cabiri | Jan 2013 | B2 |
8425468 | Weston | Apr 2013 | B2 |
8512295 | Evans et al. | Aug 2013 | B2 |
8523803 | Favreau | Sep 2013 | B1 |
8551046 | Causey et al. | Oct 2013 | B2 |
8562364 | Lin et al. | Oct 2013 | B2 |
8603026 | Favreau | Dec 2013 | B2 |
8603027 | Favreau | Dec 2013 | B2 |
8622966 | Causey et al. | Jan 2014 | B2 |
8915882 | Cabiri | Dec 2014 | B2 |
8979802 | Woehr | Mar 2015 | B2 |
9011164 | Filman et al. | Apr 2015 | B2 |
9072827 | Cabiri | Jul 2015 | B2 |
9149575 | Cabiri | Oct 2015 | B2 |
9173997 | Gross et al. | Nov 2015 | B2 |
D747799 | Norton et al. | Jan 2016 | S |
9259532 | Cabiri | Feb 2016 | B2 |
9314569 | Causey et al. | Apr 2016 | B2 |
9345836 | Cabiri et al. | May 2016 | B2 |
9350634 | Fadell | May 2016 | B2 |
9393365 | Cabiri | Jul 2016 | B2 |
9421323 | Cabiri et al. | Aug 2016 | B2 |
9452261 | Alon | Sep 2016 | B2 |
9522234 | Cabiri | Dec 2016 | B2 |
9539388 | Causey et al. | Jan 2017 | B2 |
9572926 | Cabiri | Feb 2017 | B2 |
9656019 | Cabiri et al. | May 2017 | B2 |
9782545 | Gross | Oct 2017 | B2 |
20010018937 | Nemoto | Sep 2001 | A1 |
20010025168 | Gross et al. | Sep 2001 | A1 |
20010034502 | Moberg et al. | Oct 2001 | A1 |
20010041869 | Causey et al. | Nov 2001 | A1 |
20020016569 | Critchlow et al. | Feb 2002 | A1 |
20020029018 | Jeffrey | Mar 2002 | A1 |
20020151855 | Douglas et al. | Oct 2002 | A1 |
20020169215 | Meng | Nov 2002 | A1 |
20030009133 | Ramey | Jan 2003 | A1 |
20030014018 | Giambattista et al. | Jan 2003 | A1 |
20030216683 | Shekalim | Nov 2003 | A1 |
20040000818 | Preuthun et al. | Jan 2004 | A1 |
20040049160 | Hsieh et al. | Mar 2004 | A1 |
20040082911 | Tiu et al. | Apr 2004 | A1 |
20040092873 | Moberg | May 2004 | A1 |
20040127857 | Shemesh et al. | Jul 2004 | A1 |
20040210196 | Bush, Jr. et al. | Oct 2004 | A1 |
20050033234 | Sadowski et al. | Feb 2005 | A1 |
20050038391 | Wittland et al. | Feb 2005 | A1 |
20050171512 | Flaherty | Aug 2005 | A1 |
20050203461 | Flaherty et al. | Sep 2005 | A1 |
20050283114 | Bresina et al. | Dec 2005 | A1 |
20060124269 | Miyazaki et al. | Jun 2006 | A1 |
20060206054 | Shekalim | Sep 2006 | A1 |
20060264888 | Moberg et al. | Nov 2006 | A1 |
20060264890 | Moberg et al. | Nov 2006 | A1 |
20060293722 | Slatkine et al. | Dec 2006 | A1 |
20070025879 | Vandergaw | Feb 2007 | A1 |
20070073228 | Mernoe et al. | Mar 2007 | A1 |
20070118405 | Campbell et al. | May 2007 | A1 |
20070167912 | Causey et al. | Jul 2007 | A1 |
20070179444 | Causey et al. | Aug 2007 | A1 |
20070185449 | Mernoe | Aug 2007 | A1 |
20070197954 | Keenan | Aug 2007 | A1 |
20070203454 | Shermer et al. | Aug 2007 | A1 |
20080033367 | Haury et al. | Feb 2008 | A1 |
20080033393 | Edwards et al. | Feb 2008 | A1 |
20080097381 | Moberg et al. | Apr 2008 | A1 |
20080215013 | Felix-Faure | Sep 2008 | A1 |
20080319383 | Byland et al. | Dec 2008 | A1 |
20090012478 | Weston | Jan 2009 | A1 |
20090076383 | Toews et al. | Mar 2009 | A1 |
20090088694 | Carter et al. | Apr 2009 | A1 |
20090093763 | Gonnelli et al. | Apr 2009 | A1 |
20090093792 | Gross et al. | Apr 2009 | A1 |
20090093793 | Gross et al. | Apr 2009 | A1 |
20090143730 | De Polo et al. | Jun 2009 | A1 |
20090204076 | Liversidge | Aug 2009 | A1 |
20090299288 | Sie et al. | Dec 2009 | A1 |
20090299290 | Moberg | Dec 2009 | A1 |
20090326459 | Shipway et al. | Dec 2009 | A1 |
20100076382 | Weston | Mar 2010 | A1 |
20100168683 | Cabiri | Jul 2010 | A1 |
20110066131 | Cabiri | Mar 2011 | A1 |
20110092915 | Olson et al. | Apr 2011 | A1 |
20110112504 | Causey et al. | May 2011 | A1 |
20110224616 | Slate et al. | Sep 2011 | A1 |
20120022496 | Causey et al. | Jan 2012 | A1 |
20120041387 | Bruggemann et al. | Feb 2012 | A1 |
20120172817 | Bruggemann et al. | Jul 2012 | A1 |
20130085457 | Schiff et al. | Apr 2013 | A1 |
20130110049 | Cronenberg et al. | May 2013 | A1 |
20130190693 | Ekman et al. | Jul 2013 | A1 |
20130245596 | Cabiri et al. | Sep 2013 | A1 |
20130267895 | Hemmingsen | Oct 2013 | A1 |
20130296799 | Degtiar et al. | Nov 2013 | A1 |
20130304021 | Cabiri et al. | Nov 2013 | A1 |
20130310753 | Cabiri | Nov 2013 | A1 |
20130331791 | Gross et al. | Dec 2013 | A1 |
20140018735 | Causey et al. | Jan 2014 | A1 |
20140121633 | Causey et al. | May 2014 | A1 |
20140148784 | Anderson et al. | May 2014 | A1 |
20140174223 | Gross et al. | Jun 2014 | A1 |
20140194854 | Tsals | Jul 2014 | A1 |
20140236087 | Alderete, Jr. et al. | Aug 2014 | A1 |
20150119798 | Gross | Apr 2015 | A1 |
20150374926 | Gross et al. | Dec 2015 | A1 |
20160030665 | Cabiri | Feb 2016 | A1 |
20160296716 | Cabiri et al. | Oct 2016 | A1 |
20160346478 | Bar-El et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
1505535 | Jun 2004 | CN |
101227943 | Jul 2008 | CN |
101448536 | Jun 2009 | CN |
101522235 | Sep 2009 | CN |
101541362 | Sep 2009 | CN |
201692438 | Jan 2011 | CN |
102378638 | Mar 2012 | CN |
1064693 | Sep 1959 | DE |
19717107 | Nov 1998 | DE |
1003581 | Nov 2000 | EP |
1219312 | Jul 2002 | EP |
1530979 | May 2005 | EP |
2770136 | Apr 1999 | FR |
H09-505758 | Jun 1997 | JP |
2002528676 | Sep 2002 | JP |
2009502273 | Jan 2009 | JP |
9307922 | Apr 1993 | WO |
9407553 | Apr 1994 | WO |
9700091 | Jan 1997 | WO |
200130421 | May 2001 | WO |
200172357 | Oct 2001 | WO |
0187384 | Nov 2001 | WO |
200238204 | May 2002 | WO |
02072182 | Sep 2002 | WO |
04000397 | Dec 2003 | WO |
2004105841 | Dec 2004 | WO |
2005072795 | Aug 2005 | WO |
2006037434 | Apr 2006 | WO |
06069380 | Jun 2006 | WO |
2006121921 | Nov 2006 | WO |
2007017052 | Feb 2007 | WO |
2007051563 | May 2007 | WO |
20070073228 | Jun 2007 | WO |
2009044401 | Apr 2009 | WO |
2009144085 | Dec 2009 | WO |
2010089313 | Aug 2010 | WO |
2011090956 | Jul 2011 | WO |
2015114158 | Aug 2015 | WO |
Entry |
---|
Office Action dated May 18, 2018 in EP 14166591.9. |
West Introduces The Daikyo Crystal Zenith RU Prefillable Syringe, Pharmaceutical Online, Jun. 2008, downloaded from webpage: http://www.pharmaceuticalonline.com/article.mvc/west-introduces-prefillable-syringe-system, Download date: Jan. 2009, original posting date: Jun. 2008, 2 pages. |
Copaxone®, Innovative Drugs, Teva Pharmaceuticals, downloaded from webpage: http://tevapharm.com/copaxone/, Download date: Jan. 2009, original posting date: unknown, 3 pages. |
Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,666 by Gross. |
Office Action dated Jul. 7, 2014 in U.S. Appl. No. 12/244,666 by Gross. |
Office Action dated Mar. 10, 2015 in U.S. Appl. No. 12/244,666 by Gross. |
Office Action dated Sep. 18, 2015 in U.S. Appl. No. 13/874,085 by Cabiri. |
Office Action dated May 25, 2016 in U.S. Appl. No. 14/874,017 by Cabiri. |
Office Action dated Jun. 10, 2016 in U.S. Appl. No. 13/964,651 by Gross. |
Int'l Search Report and Written Opinion dated May 13, 2009 in Int'l Application No. PCT/IL2008/001312. |
Int'l Preliminary Report on Patentability dated Apr. 7, 2010 in Int'l Application No. PCT/IL2008/001312. |
Office Action dated May 3, 2012 in CN Application No. 200880117084.X. |
Office Action dated Jan. 30, 2013 in CN Application No. 200880117084.X. |
Office Action dated Aug. 15, 2013 in CN Application No. 200880117084.X. |
Office Action dated Mar. 5, 2014 in CN Application No. 200880117084.X. |
Extended Search Report dated Feb. 23, 2015 in EP Application No. 14166596.8. |
Search Report dated Nov. 24, 2015 in EP Application No. 14166592.7. |
Extended Search Report dated Mar. 8, 2016 in EP Application No. 14166592.7. |
Extended Search Report dated Feb. 23, 2015 in EP Application No. 14166591.9. |
Office Action dated Jan. 8, 2013 in JP Application No. 2010-527595. |
Int'l Search Report dated Oct. 12, 2011 in Int'l Application No. PCT/US2011/021605. |
Int'l Written Opinion dated Jul. 19, 2012 in Int'l Application No. PCT/US2011/021605. |
Int'l Preliminary Report on Patentability dated Feb. 7, 2013 in Int'l Application No. PCT/US2011/021605. |
Office Action dated Nov. 5, 2013 in JP Application No. 2010-527595. |
Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,688 by Gross. |
Extended Search Report dated Aug. 7, 2014 in EP Application No. 14171477.4. |
Office Action dated Nov. 2, 2014 in CN Application No. 201180006571.0. |
Office Action dated Jun. 2, 2016 in CN Application No. 2014101783189. |
Search Report dated Oct. 14, 2016 in CN Application No. 2014101783742. |
Office Action dated Oct. 28, 2016 in CN Application No. 2014101783742. |
Office Action dated Nov. 10, 2016 in U.S. Appl. No. 13/874,121, by Degtiar. |
Office Action dated Nov. 25, 2016 in U.S. Appl. No. 13/874,017, by Cabiri. |
Office Action dated Oct. 5, 2016 in U.S. Appl. No. 13/964,651, by Gross. |
Office Action dated Dec. 9, 2016 in U.S. Appl. No. 14/593,051, by Gross. |
Office Action dated Jan. 10, 2017 in U.S. Appl. No. 14/193,692, by Gross. |
Office Action dated Feb. 16, 2017 in CN Application No. 2014101783189. |
Extended European Search Report dated Nov. 10, 2016 in EP Application No. 08808111.2. |
Office Action dated Feb. 24, 2017 in U.S. Appl. No. 13/964,651, by Gross. |
Extended European Search Report dated Feb. 13, 2017 in EP Application No. 16171626.1. |
Office Action dated May 24, 2017 in U.S. Appl. No. 13/874,121, by Degtiar. |
Extended European Search Report dated Jul. 3, 2017 in EP Application No. 16190054.3. |
Office Action dated May 4, 2017 in CN Application No. 2014101836665. |
Office Action dated Jun. 9, 2017 in EP Application No. 14166596.8. |
Int'l Search Report and Written Opinion dated Jul. 6, 2017 in Int'l Application No. PCT/US2017/022966. |
Office Action dated Jul. 3, 2017 in CN Application No. 2014101783742. |
Office Action dated Aug. 14, 2017 in CN Application No. 201410178318.9. |
Office Action dated Sep. 28, 2017 in IN Application No. 2528/DELNP/2010. |
Office Action dated Nov. 8, 2017 in U.S. Appl. No. 13/874,121, by Degtiar. |
Office Action dated Mar. 30, 2018 in U.S. Appl. No. 14/850,450 by Gross. |
Office Action dated Mar. 1, 2018 in EP Application No. 14166592.7. |
Office Action dated Dec. 4, 2017 in CN Application No. 201410178374.2. |
Office Action dated Nov. 13, 2017 in U.S. Appl. No. 14/193,692, by Gross. |
Office Action dated Jun. 14, 2018 in U.S. Appl. No. 13/874,121, by Degtiar. |
Office Action dated May 14, 2018 in EP Application No. 08808111.2. |
Number | Date | Country | |
---|---|---|---|
20170312450 A1 | Nov 2017 | US |
Number | Date | Country | |
---|---|---|---|
60997459 | Oct 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14593051 | Jan 2015 | US |
Child | 15655068 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12244666 | Oct 2008 | US |
Child | 14593051 | US |